Compass Therapeutics, Inc.

NASDAQ:CMPX

Biotechnology

Healthcare
$0.61 -1.46%

-$0.03 today

Market cap
$109.26M
Beta
0.74
P/E (TTM)
-5.5
EPS (TTM)
-$0.37
52W Low $1.61High $6.88

Volume 2.90M

Average 7.64M

CMPX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Compass Therapeutics, Inc.NASDAQ: CMPX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2024
-5808.8%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How CMPX compares with its peers on the latest reported figures

CMPX Competitors Peer median
Net Margin for CMPX and competitors
Company Period LTM level YoY 3-year change
OMEROmeros CorporationLTM Mar 2026871.0% ——
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-37.5% +530.6 pp+73239.9 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-119.4% ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-182.3% +766943.8 pp+3271.0 pp
GOSSGossamer Bio, Inc.LTM Mar 2026-324.8% -283.7 pp—
BCYCBicycle Therapeutics plcLTM Mar 2026-345.0% +445.1 pp+477.7 pp
OCGNOcugen, Inc.LTM Mar 2026-1605.2% -334.1 pp+1951.5 pp
CMPXCompass Therapeutics, Inc.FY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
MNPRMonopar Therapeutics Inc.FY2025— ——
FULCFulcrum Therapeutics, Inc.FY2025— ——
Peer median (excluding CMPX) -182.3%+445.1 pp+2611.2 pp

Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000850K0
Cost of Revenue00001.47M
Gross Profit000850K(1.47M)
Gross Margin———100.0%—
Research & Development20.34M30M38.12M42.34M55.97M
Selling, General & Admin10.93M11.66M12.24M15.13M16.87M
Operating Expenses81.88M41.66M50.36M57.48M71.37M
Depreciation & Amortization1.62M1.9M1.89M1.75M1.47M
EBITDA(80.19M)(34.96M)(40.6M)(47.62M)(65.02M)
EBITDA Margin———-5602.6%—
Operating Income(81.88M)(41.66M)(50.36M)(56.63M)(72.84M)
Operating Margin———-6661.8%—
Interest Income29K2.36M7.9M7.3M6.35M
Interest Expense370K2.36M000
Other Income / Expenses(299K)2.43M7.87M7.25M6.35M
Income Before Tax(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Pre-Tax Margin———-5808.8%—
Income Tax Expense00000
Net Income(82.18M)(39.23M)(42.49M)(49.38M)(66.49M)
Net Margin———-5808.8%—
EPS (Basic)(1.31)(0.35)(0.33)(0.36)(0.42)
EPS (Diluted)(1.31)(0.35)(0.33)(0.36)(0.42)
Weighted Avg Shares62.87M105.19M127.03M137.11M157.7M
Weighted Avg Shares (Diluted)62.87M105.19M127.03M137.11M157.7M

Compass Therapeutics, Inc.

NASDAQ:CMPX

Intrinsic Alpha fair value

Locked

Current Price

$0.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.